Maarten van der Doelen

Impact of DNA damage repair defects on response to radium-223 therapy in mCRPC patients

Supplementary table 3. Administered subsequent systemic therapies after radium-223. Complete cohort a N = 91 Group DDR - N = 65 Group DDR + N = 26 P

0.007

Number of subsequent therapies, median (IQR)

1 (1-2)

1 (0-2)

2 (1-3)

None, n (%)

21 (23.1)

17 (26.2)

4 (15.4)

0.409

Docetaxel chemotherapy, n (%)

20 (22.0)

16 (24.6)

4 (15.4)

0.411

Cabazitaxel chemotherapy, n (%) b

27 (29.7)

18 (27.7)

9 (34.6)

0.514

Carboplatin chemotherapy, n (%) c

4 (4.4)

2 (3.1)

2 (7.7)

0.322

Abiraterone, n (%)

25 (27.5)

17 (26.2)

8 (30.8)

0.656

Enzalutamide, n (%)

21 (23.1)

13 (20.0)

8 (30.8)

0.271

Radium-223 retreatment, n (%)

5 (5.5)

2 (3.1)

3 (11.3)

0.139

0.020

PSMA radioligand therapy, n (%)

19 (20.9)

9 (13.8)

10 (38.5)

<0.001

PARP inhibitor, n (%)

9 (9.9)

1 (1.5)

8 (30.8)

Immunotherapy, n (%) d

10 (11.0)

6 (9.2)

4 (15.4)

0.463

Other drugs, n ¸(%)

6 (6.6)

5 (7.7)

1 (3.8)

0.670

a Data on subsequent therapies were missing in 2 patients (2.2%). b Including patients (n=4) who underwent Cabazitaxel plus Carboplatin chemotherapy. c Combined with Cabazitaxel chemotherapy in all cases.

d Immunotherapy group included experimental treatment with Atezolizumab (n=1), Ipilimumab plus Nivolumab (n=5), Pembrolizumab (n=3), PSMA-ADC antibody therapy (n=1), and Nivolumab (n=1). One patient was treated with Atezolizumab and subsequently with Nivolumab. e Other drugs included experimental treatment with Bipolar androgen therapy (n=1), Cabozantinib (n=1), Cobimetinib (n=1), Cyclophosphamide (n=2), and Mitoxantrone (n=1). DDR, DNA damage repair; IQR, interquartile range; PARP, poly (ADP-ribose) polymerase; PSMA, prostate-specific membrane antigen.

7

193